IDH2 and glioma: Other studies demonstrated that IDH mutant human gliomas had reduced levels of CD8+T lymphocytes compared to their WT counterpart; this was also confirmed using a syngenic mouse model of glioma, where expression of mutant IDH or treatment with 2-HG reduced the infiltration of cytotoxic CD8+T lymphocytes and levels of T-cell-associated chemokines within tumours.